Document is current
Any future updates will be listed below
-
Authors
Ambati, Jayakrishna https://orcid.org/0000-0003-1622-6365
Magagnoli, Joseph
Leung, Hannah
Wang, Shao-bin https://orcid.org/0000-0002-6699-9406
Andrews, Chris A.
Fu, Dongxu
Pandey, Akshat
Sahu, Srabani
Narendran, Siddharth
Hirahara, Shuichiro
Fukuda, Shinichi https://orcid.org/0000-0002-4160-8229
Sun, Jian
Pandya, Lekha
Ambati, Meenakshi
Pereira, Felipe
Varshney, Akhil
Cummings, Tammy
Hardin, James W. https://orcid.org/0000-0003-0506-5500
Edun, Babatunde
Bennett, Charles L.
Ambati, Kameshwari
Fowler, Benjamin J.
Kerur, Nagaraj
Röver, Christian https://orcid.org/0000-0002-6911-698X
Leitinger, Norbert
Werner, Brian C. https://orcid.org/0000-0002-7956-2123
Stein, Joshua D.
Sutton, S. Scott https://orcid.org/0000-0002-3889-6178
Gelfand, Bradley D.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY028027)
- License Information
-
More Information
Article History
Received: 1 August 2019
Accepted: 27 August 2020
First Online: 23 September 2020
Competing interests
: J.A. is a co-founder of Inflammasome Therapeutics, iVeena Holdings, and iVeena Delivery Systems, and has received consultancy fees from Allergan, Biogen, Boehringer-Ingelheim, Immunovant, Janssen, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences unrelated to this work. J.A., B.D.G., N.K., S.W., S.F., K.A., S.N., M.A., F.P. and B.J.F. are named as inventors on patent applications filed by or patents issued to the University of Virginia or the University of Kentucky relating to DICER1, <i>Alu</i>, and inflammasome. J.W.H. has received consulting fees from Celgene Corporation unrelated to this work. S.S.S. has received research grants from Boehringer Ingelheim, Gilead Sciences, Portola Pharmaceuticals, and United Therapeutics unrelated to this work. The other authors declare no competing interests.
